K.C.C. de Bie
Papers
2
Total Citations
18
H-Index
2
About
K.C.C. de Bie is a clinical researcher advancing precision oncology in prostate cancer, with a focus on integrating molecular imaging into surgical and salvage treatment decisions. Their work centers on the prognostic and therapeutic value of prostate-specific membrane antigen (PSMA) PET/CT, particularly in patients with biochemical recurrence after robot-assisted radical prostatectomy. In a key 2023 study (14 citations), de Bie demonstrated that higher preoperative SUVmax—a measure of PSMA tracer avidity—is significantly associated with increased risk of biochemical recurrence, establishing a novel imaging biomarker for risk stratification. Expanding on this, de Bie developed and internally validated a nomogram (2024, 4 citations) that predicts outcomes of salvage radiation therapy specifically for patients without metastases on restaging PSMA PET/CT, offering a practical tool to guide personalized salvage strategies. This work bridges the gap between advanced imaging and clinical decision-making, helping to refine patient selection for local versus systemic therapy. By linking quantitative PET metrics to long-term oncologic outcomes, de Bie’s research contributes to a more precise, imaging-informed paradigm in prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1
- 2